Isoliquiritigenin induces apoptosis and inhibits xenograft tumor growth of human lung cancer cells by targeting both wild type and L858R/T790M mutant EGFR

Journal of Biological Chemistry

Volumn 289, Issue 52, 2014, Pages 35839-35848

  Jung, Sung Keun ^a,b   Lee, Mee Hyun ^a,c   Lim, Do Young ^a   Kim, Jong Eun ^a,d   Singh, Puja ^a   Lee, Sung Young ^a   Jeong, Chul Ho ^a,e   Lim, Tae Gyu ^a,f   Chen, Hanyong ^a   Chi, Young In ^a   Kundu, Joydeb Kumar ^e   Lee, Nam Hyouck ^b   Lee, Charles C ^a,g   Cho, Yong Yeon ^c   Bode, Ann M ^a   Lee, Ki Won ^d,f,h   Dong, Zigang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Korea Food Research Institute   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Seoul National University   (South Korea)

^e Keimyung University   (South Korea)

^f Seoul National University   (South Korea)

^g NONE   (United States)

^h Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BIOLOGICAL MATERIALS; BIOLOGICAL ORGANS; CATALYST ACTIVITY; CELL DEATH; CELL GROWTH; CYTOLOGY; DISEASES; DRUG PRODUCTS; ENZYMES; FLAVONOIDS; HYDROGEN BONDS; PHOSPHORYLATION; TUMORS;

ANTICANCER ACTIVITIES; CHALCONE DERIVATIVES; EPIDERMAL GROWTH FACTOR RECEPTORS; GENETIC ALTERATIONS; HUMAN LUNG CANCER CELLS; ISOLIQUIRITIGENIN; NON SMALL CELL LUNG CANCER; TYROSINE KINASE INHIBITOR;

CELLS;

ADENOSINE TRIPHOSPHATE; ASPARTIC ACID; BIM PROTEIN; CASPASE 3; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GLUTAMIC ACID; ISOLIQUIRITIGENIN; KI 67 ANTIGEN; LYSINE; METHIONINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; CHALCONE DERIVATIVE; EGFR PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BINDING;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; LUNG CANCER CELL LINE; MOLECULAR DOCKING; MOLECULARLY TARGETED THERAPY; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TREATMENT DURATION; TUMOR GROWTH; 3T3 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENETICS; HEK293 CELL LINE; LUNG NEOPLASMS; METABOLISM; MISSENSE MUTATION; NUDE MOUSE; PATHOLOGY; PROTEIN PROCESSING; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHALCONES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEK293 CELLS; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MUTATION, MISSENSE; NIH 3T3 CELLS; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937120687     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.585513     Document Type: Article

References (37)

1. Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., and Forman, D. (2011) Global cancer statistics. CA Cancer J. Clin. 61, 69-90
2. Sacco, P. C., Maione, P., Rossi, A., Barecshino, M. A., Sgambato, A., Casaluce, F., Napolitano, A., Palazzolo, G., Rossi, E., Ferrara, C., and Gridelli, C. (2014) The PI3k inhibitors: new hopes in the battle against advanced NSCLC. Front Biosci. 19, 259-271
3. John, T., Liu, G., and Tsao, M. S. (2009) Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene 28, S14-23
4. Pallis, A. G., and Syrigos, K. N. (2013) Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC. Lung Cancer 80, 120-130
5. Nguyen, T. T., Tran, E., Nguyen, T. H., Do, P. T., Huynh, T. H., and Huynh, H. (2004) The role of activated MEK-ERK pathway in quercetin-induced growth inhibition and apoptosis in A549 lung cancer cells. Carcinogenesis 25, 647-659
6. West, L., Vidwans, S. J., Campbell, N. P., Shrager, J., Simon, G. R., Bueno, R., Dennis, P. A., Otterson, G. A., and Salgia, R. (2012) A novel classification of lung cancer into molecular subtypes. PLoS One 7, e31906
7. Li, R. C., Zheng, L. J., Fang, M. H., and Yu, S. Y. (2014) The presence of EGFR mutations predicts the response in Chinese non-small cell lung cancer patients treated with erlotinib. Int. J. Biol. Markers 29, e112-e119
8. Carrera, S., Buque, A., Azkona, E., Aresti, U., Calvo, B., Sancho, A., Arruti, M., Nuno, M., Rubio, I., de Lobera, A. R., Lopez, C., and Vivanco, G. L. (2014) Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies. Clin. Transl. Oncol. 16, 339-350
9. Ma, C., Wei, S., and Song, Y. (2011) T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J. Thorac. Dis. 3, 10-18
10. Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., and Halmos, B. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792
11. Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., and Varmus, H. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73
12. Haraguchi, H., Ishikawa, H., Mizutani, K., Tamura, Y., and Kinoshita, T. (1998) Antioxidative and superoxide scavenging activities of retrochalcones in Glycyrrhiza inflata. Bioorg. Med. Chem. 6, 339-347
13. Chin, Y. W., Jung, H. A., Liu, Y., Su, B. N., Castoro, J. A., Keller, W. J., Pereira, M. A., and Kinghorn, A. D. (2007) Anti-oxidant constituents of the roots and stolons of licorice (Glycyrrhiza glabra). J. Agric. Food Chem. 55, 4691-4697
14. Kim, J. Y., Park, S. J., Yun, K. J., Cho, Y. W., Park, H. J., and Lee, K. T. (2008) Isoliquiritigenin isolated from the roots of Glycyrrhiza uralensis inhibits LPS-induced iNOS and COX-2 expression via the attenuation of NF-κB in RAW 264.7 macrophages. Eur. J. Pharmacol. 584, 175-184
15. Cuendet, M., Guo, J., Luo, Y., Chen, S., Oteham, C. P., Moon, R. C., van Breemen, R. B., Marler, L. E., and Pezzuto, J. M. (2010) Cancer chemopreventive activity and metabolism of isoliquiritigenin, a compound found in licorice. Cancer Prev. Res. 3, 221-232
16. Hsu, Y. L., Kuo, P. L., and Lin, C. C. (2005) Isoliquiritigenin induces apoptosis and cell cycle arrest through p53-dependent pathway in Hep G2 cells. Life Sci. 77, 279-292
17. Yuan, X., Zhang, B., Chen, N., Chen, X. Y., Liu, L. L., Zheng, Q. S., and Wang, Z. P. (2012) Isoliquiritigenin treatment induces apoptosis by increasing intracellular ROS levels in HeLa cells. J. Asian Nat. Prod. Res. 14, 789-798
18. Zhang, X., Yeung, E. D., Wang, J., Panzhinskiy, E. E., Tong, C., Li, W., and Li, J. (2010) Isoliquiritigenin, a natural anti-oxidant, selectively inhibits the proliferation of prostate cancer cells. Clin. Exp. Pharmacol. Physiol. 37, 841-847
19. Zhou, G. S., Song, L. J., and Yang, B. (2013) Isoliquiritigenin inhibits proliferation and induces apoptosis of U87 human glioma cells in vitro. Mol. Med. Rep. 7, 531-536
20. Chen, X., Wu, Y., Jiang, Y., Zhou, Y., Wang, Y., Yao, Y., Yi, C., Gou, L., and Yang, J. (2012) Isoliquiritigenin inhibits the growth of multiple myeloma via blocking IL-6 signaling. J. Mol. Med. 90, 1311-1319
21. Li, Y., Zhao, H., Wang, Y., Zheng, H., Yu, W., Chai, H., Zhang, J., Falck, J. R., Guo, A. M., Yue, J., Peng, R., and Yang, J. (2013) Isoliquiritigenin induces growth inhibition and apoptosis through downregulating arachidonic acid metabolic network and the deactivation of PI3K/Akt in human breast cancer. Toxicol. Appl. Pharmacol. 272, 37-48
22. Wang, Z., Wang, N., Han, S., Wang, D., Mo, S., Yu, L., Huang, H., Tsui, K., Shen, J., and Chen, J. (2013) Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway. PLoS One 8, e68566
23. Kwon, G. T., Cho, H. J., Chung, W. Y., Park, K. K., Moon, A., and Park, J. H. (2009) Isoliquiritigenin inhibits migration and invasion of prostate cancer cells: possible mediation by decreased JNK/AP-1 signaling. J. Nutr. Biochem. 20, 663-676
24. Wang, K. L., Hsia, S. M., Chan, C. J., Chang, F. Y., Huang, C. Y., Bau, D. T., and Wang, P. S. (2013) Inhibitory effects of isoliquiritigenin on the migration and invasion of human breast cancer cells. Expert Opin. Ther. Targets 17, 337-349
25. Yamazaki, S., Morita, T., Endo, H., Hamamoto, T., Baba, M., Joichi, Y., Kaneko, S., Okada, Y., Okuyama, T., Nishino, H., and Tokue, A. (2002) Isoliquiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma. Cancer Lett. 183, 23-30
26. Hsu, Y. L., Kuo, P. L., Chiang, L. C., and Lin, C. C. (2004) Isoliquiritigenin inhibits the proliferation and induces the apoptosis of human non-small cell lung cancer a549 cells. Clin. Exp. Pharmacol. Physiol. 31, 414-418
27. Ii, T., Satomi, Y., Katoh, D., Shimada, J., Baba, M., Okuyama, T., Nishino, H., and Kitamura, N. (2004) Induction of cell cycle arrest and p21(CIP1/WAF1) expression in human lung cancer cells by isoliquiritigenin. Cancer Lett. 207, 27-35
28. Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C. M., Zhao, X., Christensen, J., Kosaka, T., Holmes, A. J., Rogers, A. M., Cappuzzo, F., Mok, T., Lee, C., Johnson, B. E., Cantley, L. C., and Jänne, P. A. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043
29. Schrödinger. (2011) Schrödinger Suite LLC, New York
30. Stamos, J., Sliwkowski, M. X., and Eigenbrot, C. (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277, 46265-46272
31. Zhou, W., Ercan, D., Chen, L., Yun, C. H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., Engen, J. R., Wong, K. K., Eck, M. J., Gray, N. S., and Jänne, P. A. (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462, 1070-1074
32. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., and Bourne, P. E. (2000) The Protein Data Bank. Nucleic Acids Res. 28, 235-242
33. Godin-Heymann, N., Bryant, I., Rivera, M. N., Ulkus, L., Bell, D. W., Riese, D. J., 2nd, Settleman, J., and Haber, D. A. (2007) Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res. 67, 7319-7326
34. Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., and Ferrin, T. E. (2004) UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612
35. Ladanyi, M., and Pao, W. (2008) Lung adenocarcinoma: guiding EGFRtargeted therapy and beyond. Mod. Pathol. 21, S16-S22
36. Trusolino, L., Bertotti, A., and Comoglio, P. M. (2010) MET signalling: principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol. 11, 834-848
37. Turke, A. B., Zejnullahu, K., Wu, Y. L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., Lindeman, N. I., Murphy, C., Akhavanfard, S., Yeap, B. Y., Xiao, Y., Capelletti, M., Iafrate, A. J., Lee, C., Christensen, J. G., Engelman, J. A., and Jänne, P. A. (2010) Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17, 77-88